Validation of cSMS in Patients with Allergic Rhinoconjunctivitis (Tree and Grass Pollens, House Dust Mites). - A NIS in Patients Receiving Depigoid as a Specific Immunotherapy
Latest Information Update: 30 Mar 2021
At a glance
- Drugs Grass pollen allergy immunotherapy (Primary)
- Indications Allergic rhinoconjunctivitis; Seasonal allergic rhinitis
- Focus Therapeutic Use
- Sponsors LETI Pharma GmbH
Most Recent Events
- 25 Mar 2021 Status changed from recruiting to completed, according to ClinicalTrials.gov
- 27 Feb 2019 New trial record